FASN inhibitors have been shown to be effective in chemoprevention of breast cancer in HER2/neu transgenic mice (Alli et al., 2005) and in reducing the incidence of chemically induced lung tumorigenesis (Orita et al., 2008). Here, ERBB2 is linked to breast carcinoma.